ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jan 2022
Last Updated on 04 Jan 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials for the prophylaxis of headaches in adults with chronic migraine who have had an inadequate response, intolerance, or contraindication to at least three migraine prophylactic medications.
Botulinum toxin type A must be administered by a neurologist.

Subsidy status

Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

MAF assistance does not apply to Botox 200 U injection vial, Dysport 300 U and 500 U injection vials, and Xeomin 50 U and 100 U injection vials.


Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine (4 Jan 2022) PES Botulinum toxin A for preventing headaches in adults with chronic migraine (Published 4 Jan 2022)